Boston, MA – November 7, 2022 – Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a poster presentation at the Society for Neuroscience (SFN) 2022 conference, to be held in San Diego, California and virtually on November 12-16, 2022.
Title: Identification of THIK-1 as a therapeutic target for Alzheimer’s disease and characterization of a selective and novel blocker
Presentation Number: 366.05
Presenter: Madhurima Dey, Neuroscientist, Cell Biology and Target Validation
Session Title: Microglia and Neurodegeneration
Presentation Time: Monday, November 14, 2022, 1:00 PM – 2:00 PM PT
For more information and registration details, see the SFN website here.
Cerevance is a private pharmaceutical company whose lead therapeutic, CVN424, a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), recently demonstrated significant and clinically meaningful efficacy in a 135-patient Phase 2 study in patients with Parkinson’s disease. The company uses its proprietary NETSseq technology platform to identify highly selective novel target proteins that are either over- or under-expressed in diseased brains. Partnering with over 20 brain banks and evaluating more than 11,000 human post-mortem brain tissue samples, Cerevance is advancing a robust pipeline of targeted treatments for patients with neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease. For additional information, please visit www.cerevance.com.
Johnna Simoes, firstname.lastname@example.org
Andrew Mielach, email@example.com, +1-646-876-5868